{"count": 3, "results": [{"_id": "2894883", "pmid": 2894883, "title": "Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.", "journal": "Br Med J (Clin Res Ed)", "authors": ["Nifedipine-Atenolol Study Review Committee"], "date": "1988-02-13T00:00:00Z", "meta_date_publication": "1988 Feb 13", "meta_volume": "296", "meta_issue": "6620", "meta_pages": "468-72", "score": 50066.69, "text_hl": "Twenty six @SPECIES_9606 @@@patients@@@ (12%) were withdrawn because of adverse effects while taking @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ compared with 19 (10%) taking @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. @DISEASE_Flushing @DISEASE_MESH:D005483 @@@Flushing@@@ and @<m>DISEASE_Tang_Hsi_Ryu_syndrome</m> @DISEASE_MESH:C536897 @@@oedema@@@ were more common after the calcium antagonist, whereas @DISEASE_Diarrhea @DISEASE_MESH:D003967 @@@diarrhoea@@@ and @DISEASE_Dyspepsia @DISEASE_MESH:D004415 @@@dyspepsia@@@ were more common after @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Nifedipine-Atenolol Study Review Committee. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee. Br Med J (Clin Res Ed). 1988 Feb 13;296(6620):468-72. PMID: 2894883", "BibTeX": "@article{2894883, title={Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.}, author={Nifedipine-Atenolol Study Review Committee}, journal={Br Med J (Clin Res Ed)}, volume={296}, number={6620}, pages={468-72}}"}}, {"_id": "22251015", "pmid": 22251015, "title": "Fasitibant chloride, a kinin B2 receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats.", "journal": "Br J Pharmacol", "authors": ["Valenti C", "Giuliani S", "Cialdai C", "Tramontana M", "Maggi CA"], "date": "2012-06-01T00:00:00Z", "doi": "10.1111/j.1476-5381.2012.01861.x", "meta_date_publication": "2012 Jun", "meta_volume": "166", "meta_issue": "4", "meta_pages": "1403-10", "score": 50051.188, "text_hl": "A combination of drugs inhibiting @DISEASE_Arthralgia @DISEASE_MESH:D018771 @@@joint pain@@@ (fasitibant chloride, des-Arg9-[Leu8]-bradykinin, @CHEMICAL_dexketoprofen_trometamol @CHEMICAL_MESH:C118296 @@@dexketoprofen@@@, @CHEMICAL_verlukast @CHEMICAL_MESH:C059141 @@@MK571@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@) and @<m>DISEASE_Tang_Hsi_Ryu_syndrome</m> @DISEASE_MESH:C536897 @@@oedema@@@ (fasitibant chloride, des-Arg9-[Leu8]-bradykinin, @CHEMICAL_verlukast @CHEMICAL_MESH:C059141 @@@MK571@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@) abolished the respective @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ response, producing inhibition comparable with that achieved with the combination of fasitibant chloride and @CHEMICAL_Dexamethasone @CHEMICAL_MESH:D003907 @@@dexamethasone@@@. ", "citations": {"NLM": "Valenti C, Giuliani S, Cialdai C, Tramontana M, Maggi CA. Fasitibant chloride, a kinin B2 receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10. PMID: 22251015", "BibTeX": "@article{22251015, title={Fasitibant chloride, a kinin B2 receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats.}, author={Valenti C and Giuliani S and Cialdai C and Tramontana M and Maggi CA}, journal={Br J Pharmacol}, volume={166}, number={4}, pages={1403-10}}"}}, {"_id": "25765931", "pmid": 25765931, "title": "Atenolol offers better protection than clonidine against cardiac injury in kainic acid-induced status epilepticus.", "journal": "Br J Pharmacol", "authors": ["Read MI", "Harrison JC", "Kerr DS", "Sammut IA"], "date": "2015-10-01T00:00:00Z", "doi": "10.1111/bph.13132", "meta_date_publication": "2015 Oct", "meta_volume": "172", "meta_issue": "19", "meta_pages": "4626-38", "score": 50049.53, "text_hl": "@CHEMICAL_Clonidine @CHEMICAL_MESH:D003000 @@@Clonidine@@@, however, failed to reduce the power of EEG frequencies. @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@Atenolol@@@ and to a lesser extent @CHEMICAL_Clonidine @CHEMICAL_MESH:D003000 @@@clonidine@@@ attenuated the cardiac hypercontraction band @DISEASE_Necrosis @DISEASE_MESH:D009336 @@@necrosis@@@, @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ infiltration, and @<m>DISEASE_Tang_Hsi_Ryu_syndrome</m> @DISEASE_MESH:C536897 @@@oedema@@@ at 48 h after KA, relative to the saline-KA group. ", "citations": {"NLM": "Read MI, Harrison JC, Kerr DS, Sammut IA. Atenolol offers better protection than clonidine against cardiac injury in kainic acid-induced status epilepticus. Br J Pharmacol. 2015 Oct;172(19):4626-38. PMID: 25765931", "BibTeX": "@article{25765931, title={Atenolol offers better protection than clonidine against cardiac injury in kainic acid-induced status epilepticus.}, author={Read MI and Harrison JC and Kerr DS and Sammut IA}, journal={Br J Pharmacol}, volume={172}, number={19}, pages={4626-38}}"}}]}